The importance of TGF-β in murine Visceral leishmaniasis

Journal of Immunology

Volumn 161, Issue 11, 1998, Pages 6148-6155

  Wilson, Mary E ^a,b,c   Young, Betty M ^a   Davidson, Beverly L ^a   Mente, Kimberly A ^a   McGowan, Stephen E ^a,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LIVER GRANULOMA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROMASTIGOTE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; VISCERAL LEISHMANIASIS;

ADENOVIRIDAE; ANIMALS; ANTIGENS, PROTOZOAN; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GRANULOMA; INTERFERON TYPE II; INTERLEUKIN-10; KINETICS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER DISEASES, PARASITIC; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; VACCINATION;

EID: 0032402259     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Wilson, M. E. 1990. Leishmaniasis. Curr. Opin. Infect. Dis. 3:420.
2. Ponce, C., E. Ponce, A. Morrison, A. Cruz, R. Kreutzer, D. McMahon-Pratt, and F. Neva. 1991. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet 337:67.
3. Gorczynski, R. M. 1982. Nature of resistance to leishmaniasis in experimental rodents. Dev. Comp. Immunol. 6:199.
4. Mock, B. A., A. H. Fortier, M. Potter, and C. A. Nacy. 1985. Genetic control of systemic Leishmania major infections: dissociation of intrahepatic amastigote replication from control by the Lsh gene. Infect. Immun. 50:588.
5. Vidal, S. M., D. Malo, K. Vogan, E. Skamene, and P. Gros. 1993. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73:469.
6. Roberts, M., J. Alexander, and J. M. Blackwell. 1990. Genetic analysis of Leishmania mexicana infection in mice: Single gene (Scl-2) controlled predisposition to cutaneous lesion development. J. Immunogenet. 17:89.
7. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231.
8. Reed, S. G., and P. Scott. 1993. T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5:524.
9. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763.
10. Carvalho, E. M., A. Barrai, D. Pedral-Sampaio, M. Barral-Netto, R. Badaró, H. Rocha, and W. D. Johnson, Jr. 1992. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165:535.
11. Murray, H. W., K. E. Squires, C. D. Miralles, M. Y. Stoeckle, A. M. Granger, A. Granelli-Piperno, and C. Bogdan. 1992. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. J. Immunol. 148:1858.
12. Kaye, P. M., and G. J. Bancroft. 1992. Leishmania donovani infection in scid mice: Lack of tissue response and in vivo macrophage activation correlates with failure to trigger natural killer cell-derived gamma interferon production in vitro. Infect. Immun. 60:4335.
13. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185:867.
14. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon γ-independent mechanism. J. Exp. Med. 171:115.
15. Heinzel, F. P., R. M. Rerko, F. Ahmed, and E. Pearlman. 1995. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:730.
16. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. H. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91:1644.
17. Ghalib, H. W., M. R. Piuvezam, Y. A. W. Skeiky, M. Siddig, F. A. Hashim, A. M. El-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92:324.
18. Barral-Netto, M., A. Barral, C. E. Brownell, Y. A. W. Skeiky, L. R. Ellingsworth, D. R. Twardzik, and S. G. Reed. 1992. Transforming growth factor-β in leishmanial infection: a parasite escape mechanism. Science 257:545.
19. Pearson, R. D., and R. T. Steigbigel. 1980. Mechanism of lethal effect of human serum upon Leishmania donovani. J. Immunol. 125:2195.
20. Stauber, L. A. 1958. Host resistance to the Khartoum strain of Leishmania donovani. Rice Inst. Pamphlets 45:80.
21. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober. 1991. Current Protocols in Immunology. John Wiley and Sons, New York.
22. Meager, A. 1991. Assays for transforming growth factor β. J. Immunol. Methods 141:1.
23. McGowan, S. E., S. K. Jackson, P. J. Olson, T. Parekh, and L. I. Gold. 1997. Exogenous and endogenous transforming growth factors-β influence elastin gene expression in cultured lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 17:25.
24. Danscher, G., G. W. Hacker, C. Hauser-Kronberger, and L. Grimelius. 1995. Trends in autometallographic silver amplification of colloidal gold particles. In Immunogold-Silver Staining: Principles, Methods, and Applications. M. A. Hayat, ed. CRC Press, New York, p. 11.
25. Gudmundsson, G., A. Bosch, B. L. Davidson, and G. W. Hunningkake. 1997. Interleukin-10 modulates the severity of hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. In press.
26. Graham, F. L., and A. J. Van Der Eb. 1973. A new technique for the assay of infectivity of human Adenovirus 5 DNA. Virology 52:456.
27. Barbosa Junior, A. A., Jr., Z. A. Andrade, and S. G. Reed. 1987. The pathology of experimental visceral leishmaniasis in resistant and susceptible lines of inbred mice. Braz. J. Med. Biol. Res. 20:63.
28. Murray, H. W. 1986. Cellular resistance to protozoal infection. Annu. Rev. Med. 37:61.
29. Crocker, P. R., J. M. Blackwell, and D. J. Bradley. 1984. Expression of the natural resistance gene Lsh in resident liver macrophages. Infect. Immun. 43:1033.
30. Zabner, J., B. W. Ramsey, D. P. Meeker, M. L. Aitken, R. P. Balfour, R. L. Gibson, J. Launspach, R. A. Moscicki, S. M. Richards, T. A. Standaert, J. Williams-Warren, S. C. Wadsworth, A. E. Smith, and M. J. Welsh. 1996. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J. Clin. Invest. 6:1504.
31. + T cell-mediated protective immunity against malaria. J. Immunol. 1268.
32. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
33. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505.
34. Sypek, J. P., C. L. Chung, S. E. H. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797.
35. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63:4894.
36. Massague, J. 1996. TGF-β signaling: receptors, transducers, and Mad proteins. Cell 85:947.
37. Pardoux, C., C. Asselin-Paturel, J. Chehimi, F. Gay, F. Mami-Chouaib, and S. Chouaib. 1997. Functional interaction between TGF-β and IL-12 in human primary allogeneic cytotoxicity and proliferative resonse. J. Immunol. 158:136.
38. Bellone, G., M. Aste-Amezaga, G. Trinchieri, and U. Rodeck. 1995. Regulation of NK cell functions by TGF-β. J. Immunol. 155:1066.
39. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann. N. Y. Acad. Sci. 685:713.
40. Vodovotz, Y., A. G. Geiser, L. Chesler, J. J. Letterio, A. Campbell, M. S. Lucia, M. B. Sporn, and A. B. Roberts. 1996. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J. Exp. Med. 183:2337.
41. Wong, H. L., G. R. Welch, M. E. Brandes, and S. M. Wahl. 1991. IL-4 antagonizes induction of FcγRIII (CD16) expression by transforming growth factor-β on human monocytes. J. Immunol. 1843.
42. Takeuchi, M., P. Alard, and J. W. Streilein. 1998. TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160:1589.
43. + T cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production. J. Immunol. 160:5719.
44. Hirsch, C. S., R. Hussain, Z. Toossi, G. Dawood, F. Shahid, and J. J. Ellner. 1996. Cross-modulation by transforming growth factor β in human tuberculosis: suppression of antigen-driven blastogenesis and interferon-γ production. Proc. Natl. Acad. Sci. USA 93:3193.
45. Van Heyningen, T. K., H. L. Collins, and D. G. Russell. 1997. IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J. Immunol. 158:330.
46. Silva, J. S., D. R. Twardzik, and S. G. Reed. 1991. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor β (TGF-β). J. Exp. Med. 174:539.
47. Gazinelli, R. T., I. P. Oswald, S. Hieny, S. L. James, and A. Sher. 1992. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β. Eur. J. Immunol. 22:2501.
48. McCabe, R., S. Meagher, and B. Mullins. 1991. Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice. Infect. Immun. 59:1633.
49. Williams, M. E., P. Caspar, I. Oswald, H. K. Sharma, O. Pankewycz, A. Sher, and S. L. James. 1995. Vaccination routes that fail to elicit protective immunity against Schistosoma mansoni induce the production of TGF-β, which downregulates macrophage antiparasitic activity. J. Immunol. 154:4693.
50. Bakane, A., M. Asano, S. Sasaki, S. Nishikawa, T. Miura, M. Kohanawa, and T. Minagawa. 1996. Transforming growth factor β is protective in host resistance against Listeria monocytogenes infection in mice. Infect. Immun. 64:3901.
51. Spaccapelo, R., L. Romani, L. Tonnetti, E. Cenci, A. Mencacci, G. Del Sero, R. Tognellini, S. G. Reed, P. Puccetti, and F. Bistoni. 1997. TGF-β is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J. Immunol. 155:1349.
52. Rodrigues, V., Jr., J. S. Da Silva, and A. Campos-Neto. 1998. Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis. Infect. Immun. 66:1233.
53. Barral, A., M. Barral-Netto, E. C. Yong, C. E. Brownell, D. R. Twardzik, and S. G. Reed. 1993. Transforming growth factor β as a virulence mechanism for Leishmania braziliensis. Proc. Natl. Acad. Sci. USA 90:3442.